Cargando…
Dexmetomidine promotes the activity of breast cancer cells through miR-199a/HIF-1α axis
BACKGROUND: Breast cancer, as one of the most common malignant tumors in women, is still a great threat to women all over the world. Dexmetomidine (DMED) is a highly selective α2-adrenergic receptor agonist, which has attracted much attention in recent years. This study aimed to clarify the potentia...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797324/ https://www.ncbi.nlm.nih.gov/pubmed/35116334 http://dx.doi.org/10.21037/tcr-21-1937 |